Trofinetide Treatment Demonstrates a Benefit Over Placebo for the Ability to Communicate in Rett Syndrome

Trofinetide was approved by the FDA for the treatment of Rett syndrome (RTT) in March 2023. Benefiting the ability to communicate in RTT is often identified as the most important caregiver goal when considering desired improvements from new therapies. This analysis reports the communication-related endpoints from the phase 3 LAVENDER study of trofinetide in RTT.

Source: Pediatric Neurology - November 23, 2023 Category: Neurology Authors: Jeffrey L. Neul, Alan K. Percy, Timothy A. Benke, Elizabeth M. Berry-Kravis, Daniel G. Glaze, Sarika U. Peters, Eric D. Marsh, Di An, Kathie M. Bishop, James M. Youakim Tags: Research Paper Source Type: research